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Background/aim: Damage to elastin fibres in coronary media might lead to coronary artery ectasia (CAE). This study evaluated
whether CAE can be distinguished by detecting circulating soluble elastin (s-elastin), which is a degradation product of elastin fibres,
and elastase, which is the main enzyme of elastin fibres.
Materials and methods: Fifty-eight patients with CAE, 58 with coronary heart disease (CHD) and 61 with relatively normal coronary
arteries, were included. Circulating s-elastin and elastase were measured, and receiver operating characteristic curves were used to
demonstrate their respective optimal cut-off values for predicting CAE.
Results: The concentrations of s-elastin and elastase were higher in the CAE group than in the CHD and relatively-normal-coronary
groups. Their cut-off values for screening of CAE were 13.148 ng/mL and 25.549 ng/mL, respectively; for sensitivity of CAE were 0.690
and 0.773, respectively; and for specificity of CAE were 0.862 and 0.571, respectively. A combination of s-elastin and elastase in series
(one of the two higher than its cut-off value) had a better sensitivity for screening for CAE, whereas their combination in parallel (both
higher than their cut-off values) had a better specificity.
Conclusion: Circulating s-elastin and elastase are promising biomarkers for assisting in CAE diagnosis.
Key words: Coronary artery ectasia, soluble elastin, elastase, biomarker

1. Introduction
Coronary artery ectasia (CAE) refers to the limited or
diffused dilatation of the coronary lumen 1.5 times larger
than the normal range [1]. Its prevalence in individuals
who underwent coronary angiography (CAG) is 1.2%–
4.9%, and more than 80% of patients with CAE have
concomitant coronary heart disease (CHD) [1,2]. CAE
is mainly characterised by myocardial ischaemic changes
and atypical angina pectoris; it could cause malignant
cardiovascular events, such as myocardial infarction,
coronary rupture, and sudden death [3]. The main
pathological change in coronary dilation is the significant
destruction of the extracellular matrix (ECM), particularly
the defect of elastic fibres in the middle coronary artery
[4,5]. Proteinases might participate in ECM destruction
[6,7], especially elastase, which degrades elastin fibres
into soluble elastin (s-elastin) [8,9]. Thus, theoretically,
CAE may be screened by detecting peripheral elastase
and s-elastin concentrations in addition to CAG and
coronary computed tomographic angiography. Therefore,
this study conducted a preliminary evaluation of s-elastin

and elastase concentrations with respect to the auxiliary
diagnosis of CAE.
2. Methods
This retrospective, case-control study was approved by
the Ethics Committee of the Beijing Friendship Hospital
and was in line with the Helsinki Declaration. All patients
signed the informed consent form. The patients had
undergone CAG at Beijing Friendship Hospital from
2015 to 2017 through either femoral or radial artery. The
images were reviewed by two independent cardiologists.
For this research, CAE was defined as the diameter of
the dilated artery exceeding 1.5 times the diameter of the
adjacent normal segment [10]. CHD (control group 1) was
defined as ≥50% stenosis of ≥1 major coronary artery [11].
The degree of coronary artery stenosis was <20% in the
relatively-normal-coronary group (control group 2). The
medical records of all patients were detailed and complete;
blood samples were collected after coronary angiography,
separated immediately, and refrigerated at −80 °C within 6
h of collection.
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For selecting patients with CAE, the following
exclusion criteria were applied: acute coronary syndrome,
cardiomyopathy, valvular heart disease, heart failure,
collagen tissue disease, vasculitis, syphilis, chronic
obstructive pulmonary disease, pulmonary hypertension,
asthma, inflammatory bowel disease, early menopause,
organic liver disease, chronic alcoholism, steroid or
antiinflammatory drugs, kidney failure, or cancer within
the last 3 months. Thus, 58 patients with CAE were
selected. Furthermore, 58 patients with CHD and 61
relatively-normal-coronary patients (from the same period
corresponding to 2015–2017) were randomly selected as
the control group. According to the Markis classification
method [5], patients with CAE were divided into four
groups based on the extent of coronary involvement: type
I — diffuse ectasia of two or three vessels, type II — diffuse
disease in one vessel and localised disease in another
vessel, type III — diffuse ectasia of one vessel only, and
type IV — localised or segmental ectasia.
Circulating s-elastin and elastase were detected
using enzyme-linked immunosorbent assay, according
to the manufacturer’s instructions (Wuhan Elabscience
Biotechnology, Wuhan, Hubei, China). First, the sandwich
double-antibody principle was used, and 100 µL of serum
samples were placed into the precoated anti-s-elastin and
anti-elastase antibody microplates. These were incubated at
37 °C for 90 min. The plates were washed, the horseradish
oxidase-labelled secondary antibody was added, and the
samples were again incubated for 2 h at 37 °C. Next, the
plates were washed again, the reaction substrate (TMB)
was added, and the samples were incubated at 37 °C for 30
min. Glacial acetic acid was used to terminate the reaction;
then, the absorbance was read at 450-nm wavelength on a
microplate reader. The final concentrations were calculated
from the corresponding standard curve.
SPSS v25.0 (IBM, Armonk, NY, USA) was used for all
statistical analyses. All data were initially analysed using
the Shapiro–Wilk test to assess for normality. Continuous
data are presented as mean ± SD when normally distributed
or median with interquartile range (IQR) when nonGaussian in distribution. For normally or nonnormally
distributed continuous data, one-way analysis of variance
or Kruskal–Wallis test was used for the multigroup
analyses, and further, Tukey’s HSD method or Dunnett
tests were employed for the pairwise analysis, respectively.
Nonparametric data were expressed as a percentage (%)
using a chi-squared test between groups. The receiver
operating curve (ROC) was used to describe the specificity
and sensitivity distribution, and optimal cut-off values
for s-elastin and elastase were selected for diagnosing
coronary dilatation. The statistical test standard was α <
0.05.

3. Results
Table 1 shows that no significant differences were observed
in most baseline characteristics, including age, sex,
hypertension prevalence, blood lipids, liver and kidney
functions, or other cardiovascular risk factors among the
three groups (all P > 0.05); significant differences were
observed only for family history of CHD and diabetes
prevalence.
Plasma s-elastin and elastase (Table 2) were
significantly higher in the CAE group than in the other
two groups. Circulating inflammation-related indicators
showed no significant differences between the CAE group
and the other two groups. For the location of ectasia, CAG
indicated that the most commonly involved vessel was the
right coronary artery (53.45%).
Figure illustrates the ROC curve for s-elastin and
elastase and presents the correlation analysis between
them. The area under curve (AUC) with 95% confidence
interval (CI) for s-elastin was 0.786 (0.714–0.858, P =
0.000). For elastase, the AUC with 95% CI was 0.775
(0.702–0.847, P = 0.000). The Pearson correlation analysis
revealed that s-elastin was significantly correlated with
elastase.
Table 3 presents the evaluation of the diagnosis
method for CAE with s-elastin and elastase. For s-elastin
and elastase, the best cut-off values were 13.148 ng/mL
and 25.549 ng/mL; the values for sensitivity were 0.690
and 0.773; and the values for specificity were 0.862 and
0.571, respectively. Further analyses showed that the
combination of s-elastin and elastase in series (one of the
two higher than its cut-off value as the diagnosis standard)
was suitable for screening CAE with a better sensitivity,
whereas their combination in parallel (both higher than
their cut-off values as the diagnosis standard) was suitable
for identifying CAE with a better specificity.
When the patients were stratified into the four Markis
subgroups (Table 4), no intergroup significant differences
were noted in plasma s-elastin and elastase concentrations.
4. Discussion
In this study, the CAE, CHD, and relatively-normalcoronary groups were balanced with most of the baseline
characters, and 95% of the patients with CAE had
concomitant CHD. On the basis of the detection of plasma
s-elastin and elastase concentrations in patients with
CAE, the possible diagnostic value of applying these two
indicators was explored: 1) Plasma s-elastin and elastase
were significantly increased in the CAE group compared
to the CHD and relatively-normal-coronary groups. 2)
The ROC curve showed that s-elastin of 13.148 ng/mL and
elastase of 25.549 ng/mL were the best cut-off values for
CAE diagnosis with acceptable values of sensitivity and
specificity. 3) The combination of s-elastin and elastase in
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Table 1. Baseline characteristics for enrolled patients
CAE (n = 58)

CHD (n = 58)

Relatively normal* (n = 61)

P

Age (years)

64.00 (58.75–73.25)

63 (55.75–69.25)

59.00 (56.00–68.00)

0.086

Sex, male (%)

35 (60.34%)

37 (63.79%)

36 (59.02%)

0.860

CHD family history, n (%)

16 (27.59%)

21 (36.21%)

8 (13.11%)

0.014a

Diabetes family history, n (%)

5 (8.62%)

10 (17.24%)

8 (13.11%)

0.403

Heart rate (beats/min)

70.57 ± 10.12

70.93 ± 10.07

72.26 ± 10.32

0.632

Hypertension, n (%)

47 (81.03%)

45 (77.59%)

41 (67.21%)

0.222

SBP (mmHg)

128.0 (120.0–136.3)

129.0 (120.5–140.0)

125.00 (114.5–136.5)

0.269

DBP (mmHg)

77.50 (70.0–85.3)

73.0 (67.0–80.0)

75.0 (69.0–80.0)

0.222

Diabetes, n (%)

29 (50.00%)

27 (46.55%)

13 (21.31%)

0.002b

Fasting glucose (mmol/L)

5.90 (5.20–6.50)

5.90 (5.00–6.50)

5.90 (4.85–7.10)

0.957

Smoking, n (%)

21 (36.21%)

25 (43.10%)

27 (44.26%)

0.683

Alcohol, n (%)

12 (20.69%)

20 (34.48%)

21 (34.43%)

0.193

BMI (kg/m2)

27.10 (24.10–28.35)

25.65 (24.00–27.36)

26.00 (23.82–28.31)

0.197

TC (mmol/L)

3.81 (3.37–4.86)

3.95 (3.36–4.70)

4.10 (3.48–4.71)

0.950

TG (mmol/L)

1.35 (1.02–1.75)

1.50 (1.06–1.85)

1.25 (0.80–2.28)

0.438

HDL-c (mmol/L)

1.02 (0.87–1.27)

1.06 (0.88–1.26)

1.14 (0.88–1.38)

0.251

LDL-c (mmol/L)

2.09 (1.75–2.79)

2.16 (1.85–2.74)

2.16 (1.72–2.56)

0.819

ALT (U/L)

20.00 (13–28.25)

18.00 (15.00–24.25)

24.00 (17.00–28.00)

0.086

BUN (mmol/L)

5.80 (4.86–6.85)

5.35 (4.36–6.15)

5.13 (4.34–6.20)

0.093

Creatinine (µmol/L)

79.80 (69.23–90.10)

76.00 (67.00–86.44)

74.00 (66.05–89.25)

0.463

P values for comparison among and between the groups. The significance level was 0.05. CHD = coronary heart disease; CAE = coronary
artery ectasia; *, Relatively normal = relatively normal coronary; SBP = systolic blood pressure; DBP = diastolic blood pressure; BMI
= body mass index; TC = total cholesterol; TG = triglyceride; HDL-c = high-density lipoprotein cholesterol; LDL-c = low-density
lipoprotein cholesterol; ALT = alanine aminotransferase; BUN = blood urea nitrogen. a, comparisons for CHD family history between
CAD and CHD, and between CAE and normal group were 0.350, 0.044, respectively; b, comparisons for diabetes prevalence between
CAD and CHD, and between CAE and normal group were 0.778, 0.001, respectively.

series (one of the two was higher than its cut-off value)
was suitable for screening CAE with a better sensitivity,
while the combination of s-elastin and elastase in parallel
(both were higher than their cut-off values) was suitable
for identifying CAE with a better specificity. 4) There was
no significant relationship among different Markis types
for s-elastin and elastase.
This research indicated that detecting peripheral
elastase and s-elastin is a promising method for screening
CAE. The characteristic pathological change for CAE is
the destruction of elastic fibres in the coronary arteries.
Coronary arteries normally comprise tens of layers of
units composed of vascular smooth muscle cells and
fibrous layers, which are mainly composed of elastic fibres
(collagen types I and III) [4]. The synthesis of elastin
in vessels ceases in adulthood [12], so its degradation
or destruction is an irreversible phenomenon. Once
degraded, the elastic fibres are broken down into s-elastin
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and polypeptide fragments, and then released into the
peripheral circulation [13]. Elastin fibres are the main
targets of neutrophil serine proteases, including elastase,
proteinase 3, and cathepsin G [14]. Thus, theoretically,
increased elastase and s-elastin concentrations in the
peripheral circulation might be indicators of coronary
artery destruction in patients with CAE. However, they can
also be elevated in patients with aneurysms in other vessels
because there might be a common underlying pathological
process for various aneurysmal diseases. Therefore, these
findings should be correlated with the patient’s atypical
angina symptoms with ischaemic changes to rule out other
aneurysmal diseases.
Appropriate diagnostic biomarkers for CAE have been
lacking because the current understanding of its pathogenesis is relatively limited due its low incidence rate and
because the pathological specimens are not easy to acquire. The most critical discovery was that CAE is a type
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Table 2. The inflammation indicators and coagulation function for all patients.
CAE (n = 58)

CHD (n =5 8)

Relatively normal* (n = 61)

P

s-elastin (ng/mL)

17.48 (13.02–25.85)

13.01 (11.91–13.38)

11.95 (9.94–13.02)

0.000a

Elastase (ng/mL)

32.56 (26.43–35.66)

25.59 (20.33–28.77)

24.38 (20.57–28.54)

0.000b

hs-CRP, mg/L

1.42 (0.67–3.66)

1.35 (0.50–3.10)

1.29 (0.43–2.44)

0.248

Leukocytes (10 /μL)

6.33 (5.24–7.34)

6.38 (5.21–8.05)

6.49 (5.43–7.28)

0.732

Neutrophils (10 /μL)

6.30 ± 1.32

6.74 ± 1.96

6.51 ± 1.46

0.338

Monocytes (103/μL)

0.37 (0.29–0.48)

0.38 (0.32–0.46)

0.39 (0.31–0.47)

0.904

Lymphocytes (10 /μL)

1.88 ± 0.56

1.79 ± 0.54

1.80 ± 0.52

0.619

N/L ratio

2.25 (1.59–2.74)

2.52 (1.77–2.98)

2.28 (1.61–2.95)

0.287

3

3

3

Ectatic vessels
LM, n (%)

16 (27.59%)

LAD, n (%)

27 (46.55%)

LCX, n (%)

26 (44.83%)

RCA, n (%)

33 (53.45%)

P values for comparison among the three groups. The significance level was 0.05. CHD = coronary heart disease; CAE = coronary
artery ectasia; *, Relatively normal = relatively normal coronary; hs-CRP = high-sensitivity C-reactive protein; N/L ratio = neutrophilto-lymphocyte ratio; LAD = left anterior descending coronary artery; LCX = left circumflex coronary artery; RCA = right coronary
artery; LM = left main coronary artery. a, comparisons for s-elastin between CAD and CHD, and between CAE and normal group were
0.000, 0.000, respectively; b, comparisons for elastase between CAD and CHD, and between CAE and normal group were 0.000, 0.000,
respectively.

Figure. ROC curves for elastase and s-elastin.
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Table 3. The diagnostic evaluations of elastase and s-elastin for patients with CAE.

-

+

-

+

Combined
in parallelc
+

-

90

29

68

51

103

16

55

64

+

18

40

8

50

22

36

4

54

Items

CAGe

s-elastina

Elastaseb

Combined
in seriesd
+

Positive prediction

57.97%

49.50%

69.23%

45.76%

Negative prediction

83.33%

89.47%

82.40%

93.22%

Positive likelihood ratio

3.04

2.01

4.62

1.73

Negative likelihood ratio

0.40

0.24

0.44

0.15

Sensitivity

0.690

0.862

0.621

0.931

Specificity

0.773

0.571

0.866

0.462

Yoden index

1.463

1.433

1.486

1.393

Diagnostic index

0.463

0.433

0.486

0.393

Coincidence rate

73.45%

66.67%

78.53%

61.58%

Missed diagnosis rate

31.00%

13.80%

37.93%

6.90%

Misdiagnosis rate

22.70%

42.90%

13.45%

53.78%

Kappa value

0.425

0.364

0.499

0.311

Kappa test

0.000

0.000

0.000

0.000

CAG, coronary angiography; CAE, coronary artery ectasia. a, s-elastin positive (or “+”), it was higher than its cut-off value 13.148 ng/
mL; b, Elastase positive (or “+”), it was higher than its cut-off value25.549 ng/mL; c, combined in parallel, both s-elastin and elastase
were higher than their cut-off values (or “+”) was the diagnosis standard; d, combined in series, any one of the two (s-elastin and
elastase) was higher than its cut-off value (or “+”) was the diagnosis standard; e, CAG positive (or “+”), CAE was diagnosed by the gold
standard CAG.

of systemic inflammatory disease [15,16]. Moreover, inflammatory cells infiltrated the coronary wall, and many
peripheral inflammatory molecules and cytokines were
also disordered, such as high-sensitivity C-reactive protein
(hs-CRP), neutrophil-to-lymphocyte ratio, red cell distribution width, interleukin (IL)-4, IL-6, IL-2, tumour necrosis factor, E-selectin, P-selectin, intercellular cell adhesion
molecule-1, and vascular cell adhesion molecule 1, as well
as the oxidant-antioxidant indicators [15,16]. However,
most of those indicators lack sensitivity or specificity when
used for CAE diagnosis, and it is challenging to connect
them to the pathological process of CAE. This study demonstrated that plasma s-elastin and elastase concentrations
had better sensitivity and specificity for diagnosing CAE;
this also makes sense from the viewpoint of pathogenesis.
A combination of s-elastin and elastase concentrations in
series increased the diagnostic sensitivity and in parallel,
provided increased specificity. Detection and quantification of s-elastin and elastase is fast, easy, and inexpensive.
In patients with atypical angina, clinicians might consider
routine examination of s-elastin and elastase for early and
convenient detection of coronary dilatation.
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5. Limitations
This study has some limitations. First, this study had
a small sample size and required to be testified by large
simple size studies and by prospective studies. Second,
follow-up observations are needed to clarify the prognoses,
survival rates, and terminal events for each group. Third,
the control group was defined as coronary artery stenosis
<20% but not normal according to current consensus.
6. Conclusion
Circulating s-elastin and elastase are promising biomarkers
for assisting CAE diagnosis with acceptable values of
sensitivity and specificity, and the auxiliary diagnosis
method by these two biomarkers makes sense theoretically
and pathologically. Further, the combination of s-elastin
and elastase in series (one of the two was higher than its
cut-off value) was with a better sensitivity for screening
CAE, while in parallel (both the two were higher than their
cut-off values) was with a better specificity for identifying
CAE.
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Table 4. The s-elastin and elastase in different Markis types.
Markis I (n = 10)

Markis II (n = 14)

Markis III (n = 26)

Markis IV (n = 8)

P

Age, years

66.20 ± 8.40

61.14 ± 9.94

65.08 ± 10.57

69.25 ± 10.71

0.320

Sex, male (%)

6 (60.00%)

10 (71.43%)

15 (57.69%)

4 (50.00%)

0.509

BMI (kg/m )

25.53 ± 4.80

28.31 ± 2.98

26.83 ± 3.10

25.93 ± 1.51

0.185

Hypertension, n (%)

10 (100.00%)

12 (85.71%)

20 (76.92%)

5 (62.50%)

0.202

SBP (mmHg)

133.5 (128.8–141.3)

121.0 (116.3–138.8)

127.00 (119.8–137.3)

127.5 (125.0–132.0)

3.456

DBP (mmHg)

136.3 ± 17.0

127.3 ± 15.6

129.2 ± 18.7

128.0 ± 5.0

0.064

Diabetes, n (%)

5 (50.00%)

9 (64.29%)

9 (34.62%)

6 (75.00%)

0.133

TC, (mmol/L)

4.00 (3.57–5.28)

4.08 (3.40–4.75)

3.64 (3.24–4.41)

4.35 (3.75–5.37)

3.328

TG, (mmol/L)

1.73 (1.22–3.16)

1.42 (0.89–1.96)

1.33 (1.06–1.54)

1.32 (0.96–1.80)

2.868

HDL-c, (mmol/L)

1.01 (0.82–1.51)

1.02 (0.79–1.30)

1.01 (0.87–1.20)

1.09 (0.96–1.31)

0.995

LDL-c, (mmol/L)

2.29 ± 0.59

2.31 ± 0.65

2.29 ± 0.87

2.69 ± 0.98

0.632

Smoking, n (%)

5 (50.00%)

6 (42.86%)

6 (23.08%)

4 (50.00%)

0.268

Alcohol, n (%)

3 (30.00%)

2 (14.29%)

4 (15.38%)

3 (37.50%)

0.469

N/L ratio

2.07 (1.66–2.71)

2.39 (1.67–2.87)

2.30 (1.51–2.62)

2.00 (1.41–3.13)

0.559

hs-CRP

0.71 (0.36–8.10)

2.20 (0.65–3.96)

2.03 (0.65–4.56)

1.14 (0.77–1.42)

1.407

ALT (U/L)

14.00 (9.75–20.75)

23.00 (19.25–30.50)

21.50 (13.00–33.75)

16.00 (14.00–20.75)

5.497

BUN (mmol/L)

5.51 (4.18–6.78)

5.59 (4.18–7.43)

5.92 (4.92–6.57)

5.80 (5.36–6.39)

0.228

Creatinine (µmol/L)

83.15 (67.75–102.50)

80.30 (71.33–90.45)

78.50 (66.33–94.30)

72.75 (65.30–77.95)

1.702

s-elastin (ng/mL)

13.90 (11.11–25.58)

25.03 (14.61–28.47)

17.26 (13.02–27.41)

17.16 (12.96–25.38)

2.515

Elastase (ng/mL)

27.10 (25.39–35.46)

33.27 (29.43–35.66)

33.38 (27.71–37.77)

28.96 (24.89–35.01)

3.250

2

P values for comparison among the four groups. The significance level was 0.05. The significance level was 0.05. CHD = coronary
heart disease; CAE = coronary artery ectasia; Control = control group; SBP = systolic blood pressure; DBP = diastolic blood pressure;
BMI = body mass index; HDL-c = high-density lipoprotein cholesterol; LDL-c = low-density lipoprotein cholesterol; TC = total
cholesterol; TG = triglyceride; hs-CRP = high-sensitivity C-reactive protein; N/L ratio = neutrophil-to-lymphocyte ratio; ALT = alanine
aminotransferase; BUN = blood urea nitrogen.
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